Public research institute in oncology, part of University of London
Cambridge and ICR researchers show NICE criteria miss up to 95% of women under 50 who will develop breast cancer within 10 years. A new model called Boadicea identifies eight times as many high-risk women, prompting calls for review and investment to implement multifactorial risk assessment across the NHS.
Recent reporting shows targeted drugs, immunotherapies and refined radiochemotherapy are prolonging life for cancer patients. Trials indicate higher survival in younger groups and expanding use of genomic profiling. New therapies are pairing with existing treatments to push back relapse and increase quality of life, though access and long-term outcomes vary.